News | September 01, 2021
Abbott launch room-temperature carbetocin in India for Postpartum Haemorrhage
PPH is associated with almost 20 per cent of maternal mortality in India
PPH is associated with almost 20 per cent of maternal mortality in India
The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
It is the only biopharmaceutical company in India to offer all three dosage strengths of the drug (125mcg, 250mcg, and 500mcg)
A treatment to prevent extreme symptoms and cut hospitalisation
The drug is indicated for mild and transient episodes of heart block
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The facility is expected to be completed in 2024
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Subscribe To Our Newsletter & Stay Updated
